Adult and Adolescent Vaccines Market to 2017 - Accelerated Development and Introduction Plans (ADIP) by GAVI Alliance to Drive Growth

Aug 02, 2011, 04:08 ET from Reportlinker

NEW YORK, Aug. 2, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Adult and Adolescent Vaccines Market to 2017 - Accelerated Development and Introduction Plans (ADIP) by GAVI Alliance to Drive Growth

http://www.reportlinker.com/p0578577/Adult-and-Adolescent-Vaccines-Market-to-2017---Accelerated-Development-and-Introduction-Plans-ADIP-by-GAVI-Alliance-to-Drive-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Adult and Adolescent Vaccines Market to 2017 - Accelerated Development and Introduction Plans (ADIP) by GAVI Alliance to Drive Growth

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Adult and Adolescent Vaccines Market to 2017 - Accelerated Development and Introduction Plans (ADIP) by GAVI Alliance to Drive Growth", which provides insights into the global vaccines market, forecast until 2017. The report provides an in-depth analysis of five vaccines, which include pneumococcal, seasonal flu, human papillomavirus, hepatitis A and hepatitis B. The report also examines the immunization schedules for the covered vaccines. In addition, the report also includes insights into the vaccines R&D pipeline.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts.

GBI Research's analysis shows that the overall global vaccines market was valued at $28 billion in 2010. The market is expected to witness growth at a CAGR of 11.5% for the forecast period, and will reach $56.7 billion by 2017. The global market revenues are expected to increase due to the introduction of new molecules which are currently in the regulatory filing stage, and those in the later stages of development. The top pharmaceutical companies in the vaccines market are GlaxoSmithKline, Sanofi, Pfizer, Novartis AG., Merck & Co. Inc, and SP-MSD. Approximately 88% of the market is covered by these six companies.

Scope

The scope of this report includes -

- Data and analysis on the global adult and adolescent vaccines market

- Annualized market data for the adult and adolescent vaccines market from 2007 to 2017 for pneumococcal vaccines, human pappilomavirus vaccines, seasonal flu vaccines, hepatitis A vaccines and hepatitis B vaccines

- Key drivers and restraints that have had a significant impact on the market

- The competitive landscape of the global vaccines market

- Key M&A activities, licensing agreements and co-development deals that took place in the vaccines market between 2009 and 2011.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.

- Devise a more tailored country strategy through the understanding of key drivers and barriers of the vaccines market.

- Develop key strategic initiatives by understanding the key focus areas and leading companies.

- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 7

1.2 List of Figures 9

2 Adult and Adolescent Vaccines Market to 2017: Introduction 11

2.1 Overview 11

2.2 GBI Research Report Guidance 12

3 Adult and Adolescent Vaccines Market to 2017: Market Overview 13

3.1 Vaccine Preventable Diseases 13

3.2 Vaccine Manufacturing Process 14

4 Adult and Adolescent Vaccines Market to 2017: Global Vaccines Market 15

4.1 Market Forecasts 15

4.2 Market Share by Diseases Sector 17

4.3 Market Share by Geography 18

4.4 Average Cost of Vaccination per Child 19

4.5 Target Population 19

4.6 Immunization Coverage 22

4.7 Unmet Needs 24

4.8 Market Trends 25

4.8.1 Immunization Programs 25

4.8.2 Public Private Partnerships 25

4.8.3 Production Capacity 26

4.8.4 Reimbursements 26

4.9 Drivers 26

4.9.1 Growth will be Driven by Vaccines Targeting New Diseases 27

4.9.2 The Adult Vaccines Segment will Provide a Significant Boost to Growth of the Market 27

4.9.3 Pediatric Combination Vaccines will Continue to Drive Growth 27

4.9.4 Availability of Vaccine Technologies That Help Increase Efficacy and Safety will Drive Innovation and Growth 27

4.9.5 Cancer and HIV/AIDS Vaccines Hold Significant Potential for the Future 27

4.10 Barriers 28

4.10.1 Limitations in Production Capacity Delay the Realization of Potential 28

4.10.2 High Initial Capital Investments and Technical Expertise Act as Entry Barriers 28

4.10.3 Lack of Harmonized Regulations Delays Vaccine Launch and Acceptance 28

5 Adult and Adolescent Vaccines Market to 2017: The US Vaccines Market 29

5.1 Market Overview 29

5.2 Market Forecasts 29

5.3 Cost of Vaccination per Child in the US 31

5.4 Immunization Schedule 32

5.5 Regulatory Framework 33

5.6 Vaccine Procurement 34

5.7 Vaccine Stockpiling 35

6 Adult and Adolescent Vaccines Market to 2017: European Vaccines Market 36

6.1 Market Overview 36

6.2 Market Forecasts 36

6.3 Average Cost of Vaccination per Child 38

6.4 Vaccine Stockpiling 38

6.5 The UK 39

6.5.1 Immunization Schedule 39

6.5.2 Regulatory Framework 39

6.5.3 Vaccine Procurement 39

6.6 France 40

6.6.1 Immunization Schedule 40

6.6.2 Regulatory Framework 41

6.6.3 Vaccine Procurement 41

6.7 Germany 42

6.7.1 Immunization Schedule 42

6.7.2 Regulatory Framework 43

6.7.3 Vaccine Procurement 44

6.8 Italy 44

6.8.1 Immunization Schedule 44

6.8.2 Regulatory Framework 44

6.8.3 Vaccine Procurement 45

6.9 Spain 45

6.9.1 Immunization Schedule 45

6.9.2 Regulatory Framework 46

6.9.3 Vaccine Procurement 47

7 Adult and Adolescent Vaccines Market to 2017: Rest of the World Vaccines Market 48

7.1 Market Overview 48

7.2 Market Forecasts 48

7.3 Average Cost of Vaccination per Child 49

7.4 Immunization Schedule 49

7.5 Regulatory Framework 49

7.6 Vaccine Procurement 49

7.7 Vaccine Stockpiling 50

8 Adult and Adolescent Vaccines Market to 2017: Pneumococcal Vaccines Market 51

8.1 Market Overview 51

8.2 Market Forecasts 51

8.3 Average Cost of Vaccination 52

8.4 Target Population 53

8.5 Immunization Coverage 54

8.6 Product Analysis 54

8.6.1 Prevnar 7 54

8.6.2 Prevnar 13 (pneumococcal 13-valent conjugate vaccine) 54

8.6.3 Pneumovax 23 55

8.6.4 Synflorix 56

8.7 Vaccine Pipeline Analysis 57

8.7.1 Phase lll 57

8.7.2 Phase ll 58

8.7.3 Phase l 58

8.7.4 Preclinical/Discovery 58

9 Adult and Adolescent Vaccines Market to 2017: Human Pappilomavirus Vaccines Market 59

9.1 Market Overview 59

9.2 Market Forecasts 59

9.3 Average Cost of Vaccination 60

9.4 Target Population 61

9.5 Immunization Coverage 62

9.6 Product Analysis 62

9.6.1 Gardasil 62

9.6.2 Cervarix 63

9.7 Vaccine Pipeline Analysis 63

9.7.1 Phase lll 63

9.7.2 Phase ll 64

9.7.3 Phase l 65

9.7.4 Preclinical/Discovery 66

10 Adult and Adolescent Vaccines Market to 2017: Seasonal Flu Vaccines Market 67

10.1 Market Overview 67

10.2 Average Cost of Vaccination 71

10.3 Target Population 72

10.4 Immunization Coverage 73

10.5 Product Analysis 73

10.5.1 Fluzone 73

10.5.2 Fluarix 73

10.6 Vaccine Pipeline Analysis 74

10.6.1 Regulatory Filed Products 74

10.6.2 Phase lll 74

10.6.3 Phase ll 75

10.6.4 Phase l 76

10.6.5 Preclinical/Discovery 77

11 Adult and Adolescent Vaccines Market to 2017: Hepatitis A Vaccines Market 79

11.1 Market Overview 79

11.2 Market Forecasts 79

11.3 Average Cost of Vaccination 80

11.4 Target Population 81

11.5 Product Analysis 82

11.5.1 Twinrix 82

11.5.2 Havrix 83

11.5.3 Vaqta 83

11.5.4 Ambirix 84

11.5.5 Avaxim 84

11.6 Vaccine Pipeline Analysis 85

11.6.1 NDA Filed Molecules 85

11.6.2 Phase lll 85

11.6.3 Preclinical/Discovery 85

12 Adult and Adolescent Vaccines Market to 2017: Hepatitis B Vaccines Market 86

12.1 Market Overview 86

12.2 Market Forecasts 87

12.3 Average Cost of Vaccination 88

12.4 Target Population 89

12.5 Product Analysis 90

12.5.1 Recombivax HB 90

12.5.2 Engerix-B 90

12.5.3 Twinrix 91

12.5.4 Comvax 91

12.6 Vaccine Pipeline Analysis 91

12.6.1 Regulatory Filed Products 91

12.6.2 Phase lll 92

12.6.3 Phase ll 93

12.6.4 Phase l 93

12.6.5 Preclinical/Discovery 94

13 Adult and Adolescent Vaccines Market to 2017: Competitive Landscape 95

13.1 Overview 95

13.2 Market Share Analysis 96

14 Adult and Adolescent Vaccines Market to 2017: Strategic Consolidations 98

14.1 Mergers & Acquisitions 98

14.1.1 Overview 98

14.1.2 Top Deals in M&A 98

14.1.3 M&A by Indication 99

14.1.4 M&A by Year 100

14.1.5 M&A by Geography 101

14.1.6 M&A by Value 102

14.2 Licensing Agreements 103

14.2.1 Overview 103

14.2.2 Top Licensing Deals 103

14.2.3 Licensing Deals by Indication 104

14.2.4 Licensing Deals by Year 105

14.2.5 Licensing Deals by Geography 106

14.2.6 Licensing Deals by Value 107

14.3 Co-Development Deals 108

14.3.1 Overview 108

14.3.2 Top Co-Development Deals 108

14.3.3 Co-Development Deals by Indication 109

14.3.4 Co-Development Deals by Year 110

14.3.5 Co-Development Deals by Geography 111

14.3.6 Co-Development Deals by Value 112

15 Appendix 113

15.1 Market Definitions 113

15.2 Abbreviations 113

15.3 Research Methodology 114

15.4 Global Vaccines Market 114

15.4.1 Coverage 114

15.4.2 Sources of Coverage 115

15.4.3 Methodology 115

15.5 Geographical Landscape 115

15.5.1 Coverage 115

15.5.2 Sources of Coverage 115

15.5.3 Methodology 115

15.6 Market Characterization 116

15.6.1 Coverage 116

15.6.2 Sources of Coverage 116

15.6.3 Methodology 116

15.7 Competitive Landscape 116

15.7.1 Coverage 116

15.7.2 Sources of Coverage 116

15.7.3 Methodology 117

15.8 Pipeline Analysis 117

15.8.1 Coverage 117

15.8.2 Sources of Coverage 117

15.8.3 Methodology 117

15.9 Strategic Consolidations 117

15.9.1 Coverage 117

15.9.2 Sources of Coverage 117

15.9.3 Methodology 117

15.10 Contact Us 117

15.11 Disclaimer 118

15.12 Sources 1181.1 List of Tables

Table 1: Adult and Adolescent Vaccines Market to 2017, Vaccine Preventable Disease, 2010 13

Table 2: Adult and Adolescent Vaccines Market to 2017, Global, Revenues ($bn), 2007-2017 15

Table 3: Adult and Adolescent Vaccines Market to 2017, Global, Market Share By Indication (%), 2010 17

Table 4: Adult and Adolescent Vaccines Market to 2017, Global, Target Pediatric Population ('000), 2007-2017 20

Table 5: Adult and Adolescent Vaccines Market to 2017, Global, Target Adult Population ('000), 2007-2017 21

Table 6: Adult and Adolescent Vaccines Market to 2017, Global, Immunization Coverage (%), 2007-2009 23

Table 7: Adult and Adolescent Vaccines Market to 2017, Global, GAVI Achievements, 2008-2010 25

Table 8: Adult and Adolescent Vaccines Market to 2017, the US, Revenues ($bn), 2007-2017 29

Table 9: Adult and Adolescent Vaccines Market to 2017, the US, Cost of Vaccination ($), 2010 31

Table 10: Adult and Adolescent Vaccines Market to 2017, Europe, Revenues ($bn), 2007-2017 37

Table 11: Adult and Adolescent Vaccines Market to 2017, Europe, Average Cost of Vaccination ($), 2009 38

Table 12: Adult and Adolescent Vaccines Market to 2017, Rest of the World, Revenues ($bn), 2007-2017 48

Table 13: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Revenues ($bn), 2007-2017 51

Table 14: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Annual Cost of Vaccination ($), 2007-2017 52

Table 15: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Target Population ('000), 2007-2017 53

Table 16: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccines, Phase lll Molecules, 2011 57

Table 17: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccines, Phase ll Molecules, 2011 58

Table 18: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccines, Phase l Molecules, 2011 58

Table 19: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccines, Preclinical / Discovery Molecules, 2011 58

Table 20: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Revenues ($bn), 2007-2017 59

Table 21: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Annual Cost of Vaccination ($), 2007-2017 60

Table 22: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Target Population ('000), 2007-2017 61

Table 23: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Product Comparison, 2007-2017 62

Table 24: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Phase lll Molecules, 2011 63

Table 25: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Phase ll Molecules, 2011 64

Table 26: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Phase l Molecules, 2011 65

Table 27: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Preclinical / Discovery Molecules, 2011 66

Table 28: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Revenues ($bn), 2007-2017 69

Table 29: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Annual Cost of Vaccination ($), 2007-2017 71

Table 30: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Target Population ('000), 2007-2017 72

Table 31: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, Regulatory Filed Molecules, 2011 74

Table 32: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, Phase lll Molecules, 2011 74

Table 33: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, Phase ll Molecules, 2011 75

Table 34: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, Phase l Molecules, 2011 76

Table 35: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, Preclinical / Discovery Molecules, 2011 77

Table 36: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Revenues ($m), 2007-2017 79

Table 37: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Annual Cost of Vaccination ($), 2007-2017 80

Table 38: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Target Population (million), 2007-2017 81

Table 39: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccines, NDA Filed Molecules, 2011 85

Table 40: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccines, Phase lll Molecules, 2011 85

Table 41: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccines, Preclinical / Discovery Molecules, 2011 85

Table 42: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Revenues ($m), 2007-2017 87

Table 43: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Annual Cost of Vaccination ($), 2007-2017 88

Table 44: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Target Population (million), 2007-2017 89

Table 45: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, Regulatory Filed Molecules, 2011 91

Table 46: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, Phase lll Molecules, 2011 92

Table 47: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, Phase ll Molecules, 2011 93

Table 48: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, Phase l Molecules, 2011 93

Table 49: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, Preclinical / Discovery Molecules, 2011 94

Table 50: Adult and Adolescent Vaccines Market to 2017, Global, Top Deals in M&A (%), 2009-2011 98

Table 51: Adult and Adolescent Vaccines Market to 2017, M&A by Indication (%), 2009-2011 99

Table 52: Adult and Adolescent Vaccines Market to 2017, M&A by Year (%), 2009-2011 100

Table 53: Adult and Adolescent Vaccines Market to 2017, M&A by Geography (%), 2009-2011 101

Table 54: Adult and Adolescent Vaccines Market to 2017, M&A by Value (%), 2009-2011 102

Table 55: Adult and Adolescent Vaccines Market to 2017, Global, Top Licensing Deals ($m), 2009-2011 103

Table 56: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Indication (%), 2009-2011 104

Table 57: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Year (%), 2009-2011 105

Table 58: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Geography (%), 2009-2011 106

Table 59: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Value (%), 2009-2011 107

Table 60: Adult and Adolescent Vaccines Market to 2017, Global, Co-Development Deals, 2009-2011 108

Table 61: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Indication (%), 2009-2011 109

Table 62: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Year (%), 2009-2011 110

Table 63: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Geography (%), 2009-2011 111

Table 64: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Value (%), 2009-2011 1121.2 List of Figures

Figure 1: Adult and Adolescent Vaccines Market to 2017, Global, Vaccine Manufacturing Process, 2010 14

Figure 2: Adult and Adolescent Vaccines Market to 2017, Global, Revenues ($bn), 2007-2017 15

Figure 3: Adult and Adolescent Vaccines Market to 2017, Global, Market Share By Indication (%), 2010 17

Figure 4: Adult and Adolescent Vaccines Market to 2017, Global, Market Share By Geography (%), 2010 18

Figure 5: Adult and Adolescent Vaccines Market to 2017, Global, Target Pediatric Population ('000), 2007-2017 19

Figure 6: Adult and Adolescent Vaccines Market to 2017, Global, Target Adult Population ('000), 2007-2017 20

Figure 7: Adult and Adolescent Vaccines Market to 2017, Global, Immunization Coverage (%), 2007-2009 22

Figure 8: Adult and Adolescent Vaccines Market to 2017, Global, Unmet Need, 2010 24

Figure 9: Adult and Adolescent Vaccines Market to 2017, Global, Drivers and Barriers, 2007-2017 26

Figure 10: Adult and Adolescent Vaccines Market to 2017, the US, Revenues ($bn), 2007-2017 29

Figure 11: Adult and Adolescent Vaccines Market to 2017, the US, Immunization Schedule, 2010 32

Figure 12: Adult and Adolescent Vaccines Market to 2017, the US, Vaccine Development and Approval Process, 2010 33

Figure 13: Adult and Adolescent Vaccines Market to 2017, the US, Vaccine Procurement, 2010 34

Figure 14: Adult and Adolescent Vaccines Market to 2017, Europe, Revenues ($bn), 2007-2017 36

Figure 15: Adult and Adolescent Vaccines Market to 2017, the UK, Immunization Schedule, 2010 39

Figure 16: Adult and Adolescent Vaccines Market to 2017, France, Immunization Schedule, 2010 40

Figure 17: Adult and Adolescent Vaccines Market to 2017, France, Distribution of Vaccine Administration by Sector, 2010 41

Figure 18: Adult and Adolescent Vaccines Market to 2017, Germany, Immunization Schedule, 2010 42

Figure 19: Adult and Adolescent Vaccines Market to 2017, Germany, Distribution of Vaccine Administration by Sector, 2010 43

Figure 20: Adult and Adolescent Vaccines Market to 2017, Italy, Immunization Schedule, 2010 44

Figure 21: Adult and Adolescent Vaccines Market to 2017, Spain, Immunization Schedule, 2010 45

Figure 22: Adult and Adolescent Vaccines Market to 2017, Spain, Distribution of Vaccine Administration by Sector, 2010 46

Figure 23: Adult and Adolescent Vaccines Market to 2017, Rest of the World, Revenues ($bn), 2007-2017 48

Figure 24: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Revenues ($bn), 2007-2017 51

Figure 25: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Annual Cost of Vaccination ($), 2007-2017 52

Figure 26: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Target Population ('000), 2007-2017 53

Figure 27: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Revenues ($bn), 2007-2017 59

Figure 28: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Annual Cost of Vaccination ($), 2007-2017 60

Figure 29: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Target Population ('000), 2007-2017 61

Figure 30: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Number of Doses Produced, 2000-2010 67

Figure 31: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Sales by Channel (%), 2009 68

Figure 32: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Vaccines Produced by Manufacturer, 2009-2010 68

Figure 33: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Revenues ($bn), 2007-2017 69

Figure 34: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Annual Cost of Vaccination ($), 2007-2017 71

Figure 35: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Target Population ('000), 2007-2017 72

Figure 36: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Revenues ($m), 2007-2017 79

Figure 37: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Annual Cost of Vaccination ($), 2007-2017 80

Figure 38: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Target Population (million), 2007-2017 81

Figure 39: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Revenues ($m), 2007-2017 87

Figure 40: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Annual Cost of Vaccination ($), 2007-2017 88

Figure 41: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Target Population (million), 2007-2017 89

Figure 42: Adult and Adolescent Vaccines Market to 2017, Market Share Analysis (%), 2009 96

Figure 43: Adult and Adolescent Vaccines Market to 2017, Market Share Analysis (%), 2010 97

Figure 44: Adult and Adolescent Vaccines Market to 2017, Strategic Consolidations (%), 2009-2011 98

Figure 45: Adult and Adolescent Vaccines Market to 2017, M&A by Indication (%), 2009-2011 99

Figure 46: Adult and Adolescent Vaccines Market to 2017, M&A by Year (%), 2009-2011 100

Figure 47: Adult and Adolescent Vaccines Market to 2017, M&A by Geography (%), 2009-2011 101

Figure 48: Adult and Adolescent Vaccines Market to 2017, M&A by Value (%), 2009-2011 102

Figure 49: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Indication (%), 2009-2011 104

Figure 50: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Year (%), 2009-2011 105

Figure 51: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Geography (%), 2009-2011 106

Figure 52: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Value (%), 2009-2011 107

Figure 53: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Indication (%), 2009-2011 109

Figure 54: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Year (%), 2009-2011 110

Figure 55: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Geography (%), 2009-2011 111

Figure 56: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Value (%), 2009-2011 112

To order this report:

Drug and Medication Industry: Adult and Adolescent Vaccines Market to 2017 - Accelerated Development and Introduction Plans (ADIP) by GAVI Alliance to Drive Growth

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com